Target intelligence / Profile preview

Hemosiderin

Molecular classification
Iron-storage complex, Protein-lipid-iron aggregate, Other
01

Overview

Hemosiderin is an insoluble, intracellular protein complex that serves as a primary form of iron storage in the body, particularly when iron levels exceed the storage capacity of ferritin (StatPearls). It consists of aggregates of ferritin, denatured ferritin, and other materials like lipids and carbohydrates, primarily found within macrophages of the liver, spleen, and bone marrow (NIH). While it plays a physiological role in sequestering potentially toxic free iron, pathological accumulation leads to visible hemosiderin staining in the skin—common in chronic venous insufficiency—or organ damage in systemic iron overload conditions like hemochromatosis (Mayo Clinic). Therapeutic targeting of hemosiderin involves the use of iron chelators, such as Deferoxamine, which mobilize iron for excretion, or dermatological interventions like Q-switched lasers that mechanically disrupt the pigment for biological clearance. The provided term 'Hemosiderin pigment removal' refers to a clinical procedure or outcome rather than a specific molecular target, which is properly identified as the hemosiderin complex itself.

Other names
Hemosiderin pigmentIron-storage complexSiderinDenatured ferritin aggregate
02

Mechanism of action

Iron chelators bind to the ferric iron (Fe3+) within the hemosiderin complex, forming stable, soluble complexes that can be excreted by the kidneys or liver (PubChem). In aesthetic applications, lasers utilize selective photothermolysis to fragment pigment particles, facilitating clearance by macrophages (StatPearls).

03

Biological functions

Iron sequestrationIntracellular iron storageHeme degradation byproduct
04

Disease associations

Chronic venous insufficiencyHemochromatosisSiderosisPost-inflammatory hyperpigmentationEcchymosis (bruising)Thalassemia
05

Safety considerations

Systemic iron depletionChelation-induced nephrotoxicityPost-laser inflammatory hyperpigmentationOcular toxicity with certain chelators
06

Interacting drugs

Deferoxamine

4 more in the full profile.

07

Biomarkers

Serum ferritinTransferrin saturationPrussian blue stain (tissue biopsy)Magnetic Resonance Imaging (MRI) R2* relaxometry

Beyond the preview

Go deeper on Hemosiderin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemosiderin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call